Sunshine Biopharma (SBFM) EBIT Margin (2015 - 2026)
Sunshine Biopharma (SBFM) reported EBIT Margin of 17.25% for Q1 2026, down 270.0% on a YoY basis from 10.15% in Q1 2025, and up 17.33% quarter-over-quarter from 20.87% in Q4 2025.
Sunshine Biopharma (SBFM) EBIT Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma has reported EBIT Margin for 10 years, with the latest figure at 17.25% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 270.0% year-over-year to 17.25%; the trailing twelve-month figure through Mar 2026 stood at 17.83% (down 207.0% YoY), and the FY2025 full-year result was 17.15%, down 49.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 17.25%, up from 20.87% in the prior quarter.
- The five-year high for EBIT Margin was 11.54% in Q3 2025, with the low at 1293.58% in Q3 2022.
- Historically, EBIT Margin has averaged 210.77% across 5 years, with a median of 18.23% in 2023.
- The largest YoY upside for EBIT Margin was 218701 bps in 2022 against a maximum downside of 30847 bps in 2022.
- Sunshine Biopharma's EBIT Margin stood at 593.01% in 2022, then jumped by 97 bps to 15.46% in 2023, then tumbled by 37 bps to 21.24% in 2024, then gained by 2 bps to 20.87% in 2025, then gained by 17 bps to 17.25% in 2026.
- The last three EBIT Margin figures came in at 17.25% (Q1 2026), 20.87% (Q4 2025), and 11.54% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Sunshine Biopharma | 10.94 Mn | 4.03 Mn | 2.18 Mn | -17.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.25% |
| Dec 31, 2025 | -20.87% |
| Sep 30, 2025 | -11.54% |
| Jun 30, 2025 | -21.83% |
| Mar 31, 2025 | -14.56% |
| Dec 31, 2024 | -21.24% |
| Sep 30, 2024 | -13.12% |
| Jun 30, 2024 | -13.63% |
| Mar 31, 2024 | -17.91% |
| Dec 31, 2023 | -15.46% |
| Sep 30, 2023 | -13.08% |
| Jun 30, 2023 | -18.23% |
| Mar 31, 2023 | -37.37% |
| Dec 31, 2022 | -593.01% |
| Sep 30, 2022 | -1,293.58% |
| Jun 30, 2022 | -462.92% |
| Mar 31, 2022 | -997.48% |
| Dec 31, 2021 | -328.52% |
| Sep 30, 2021 | -985.11% |
| Jun 30, 2021 | -734.95% |